

STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Services Prior Authorization Criteria

Cabenuva® (Cabotegravir and Rilpivirine)

Effective 9/22/2021

Prior Authorization Request Form

CABENUVA, a 2-drug co-packaged product of cabotegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

"Cabenuva requires review by the Medical Director and is available only on appeal. Medical reasoning beyond convenience or enhanced compliance over preferred agents must be provided."

Note: The healthcare provider and patient may decide to use an oral lead-in with oral cabotegravir and oral rilpivirine prior to the initiation of CABENUVA to assess the tolerability of cabotegravir and rilpivirine, or the healthcare provider and patient may proceed directly to injection of CABENUVA without the use of an oral lead-in.

Oral lead-in therapy will not qualify as stabilization of treatment. Cabenuva will only be grandfathered for patients established on therapy.

Oral lead-in with Vocabria® (cabotegravir) and Edurant® (rilpivirine) are provided at no charge by the manufacturer and should be dispensed ONLY for those who have already obtained prior approval of Cabenuva.

The use of pharmaceutical samples will not be considered when evaluating the members' medical condition or prior prescription history for drugs that require prior authorization.

References:

- 1.) Cabenuva Package Insert (revised 3/2022)
- 2.) LexiComp monograph on Cabenuva (reviewed 9/2021,8/2022)

DUR Board Approval: 9/22/2021 PS

Updated: 8/10/2022 PS